ADMA BIOLOGICS CLASS ACTION DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges ADMA Biologics, Inc. Stockholders to Contact the Firm Regarding Their Rights Before August 10th

ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired ADMA Biologics securities between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”). Investors have until August 10, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. What are the Allegation Details? The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding ADMA’s business, operations, and prospects, including allegations that: (1) ADMA engaged in an undisclosed related party transaction; (2) ADMA used channel stuffing to create an appearance of revenue; and (3) ADMA lacked adequate internal controls. On March 24, 2026, Culper Research published a short report on ADMA, alleging that "ADMA's reported growth is a fiction driven more than entirely by a de facto channel stuffing scheme and an undisclosed related party distributor" and "estimat[ing] that, absent channel stuffing, ADMA revenues declined 3% in 2025 vs. +20% reported." Following publication of the Culper report, ADMA's stock price fell $2.26 per share, or 16.63%, to close at $11.33 per share on March 24, 2026. What are my Next Steps? If you purchased or otherwise acquired ADMA shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected] , telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn. Contact Information: Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 [email protected] www.bespc.com Tags ADMA Biologics ADMA class action complaint Brandon Walker Bragar Eagel & Squire Melissa Fortunato BES lawsuit stockholder shares Class Action GlobeNewswire Recommended Reading August 03, 2026 18:27 ET | Source: Bragar Eagel & Squire ERASCA LEAD PLAINTIFF DEADLIN...